Fig. 2: KCTD21-AS1 promoted NSCLC cell proliferation in vitro and in vivo.

a qRT-PCR results showed KCTD21-AS1 expression in the lv-KCTD21-AS1-treated A549 cells. Data were shown as mean ± SD for triplicate experiments. **p < 0.01; Student’s t-test. b CCK8 assay illustrated that cell proliferation was promoted in KCTD21-AS1-treated A549 cells. Data were shown as mean ± SD for triplicate experiments. *p < 0.05, **p < 0.01; ANOVA. c siRNA inhibited KCTD21-AS1 expression in A549 cells. Data were shown as mean ± SD for triplicate experiments. **p < 0.01; Student’s t-test. d CCK8 assay. siRNA obviously inhibited A549 cell proliferation. Data were shown as mean ± SD for triplicate experiments. *p < 0.05, **p < 0.01; ANOVA. e, f The colony numbers of A549 cells infected with lv-KCTD21-AS1 or lv-siR-KCTD21-AS1 were analyzed. Data were shown as the mean ± SD for triplicate experiments. *p < 0.05, **p < 0.01; Student’s t-test. g–i Tumor size, weight, and volume changes of KCTD21-AS1-overexpressed xenografts in nude mice. Data were shown as median (interquartile range) or mean ± SD. n = 5, *p < 0.05, **p < 0.01; Mann–Whitney U test or Student’s t-test. j–l Tumor size, weight, and volume changes of siRNA-treated xenografts were measured. Data were shown as median (interquartile range) or mean ± SD. n = 5, **p < 0.01; Mann–Whitney U test or Student’s t-test.